

**Mouse Cblb Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP19220b****Specification**

---

**Mouse Cblb Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q3TTA7](#)**Mouse Cblb Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 208650**Other Names**

E3 ubiquitin-protein ligase CBL-B, 632-, Casitas B-lineage lymphoma proto-oncogene b, SH3-binding protein CBL-B, Signal transduction protein CBL-B, Cblb

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**Mouse Cblb Antibody (C-term) Blocking Peptide - Protein Information****Name** Cblb**Function**

E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (PubMed:<a href="http://www.uniprot.org/citations/29237719" target="\_blank">29237719</a>).

**Cellular Location**

Cytoplasm. Note=In adipocytes, translocates to the plasma membrane upon insulin stimulation

## **Mouse Cblb Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## **Mouse Cblb Antibody (C-term) Blocking Peptide - Images**

## **Mouse Cblb Antibody (C-term) Blocking Peptide - Background**

E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. May also be involved in EGFR ubiquitination and internalization.

## **Mouse Cblb Antibody (C-term) Blocking Peptide - References**

Wilson, B.G., et al. Cancer Cell 18(4):316-328(2010) Stromnes, I.M., et al. J. Clin. Invest. 120(10):3722-3734(2010) Naramura, M., et al. Proc. Natl. Acad. Sci. U.S.A. 107(37):16274-16279(2010) Teh, C.E., et al. Proc. Natl. Acad. Sci. U.S.A. 107(33):14709-14714(2010) Huang, H., et al. Immunity 33(1):60-70(2010)